Plus Therapeutics News

Plus Therapeutics | 8-K: Current report

May 9 16:24

Plus Therapeutics | 8-K: Current report

Mar 14 16:07

Plus Therapeutics | 8-K: Current report

Mar 13 07:03

Plus Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Mar 8 15:32

Plus Therapeutics | 8-K: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5 15:13

Plus Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Nov 22, 2023 15:08

Plus Therapeutics | 8-K: Current report

Nov 20, 2023 06:01

Plus Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Nov 13, 2023 19:15

Plus Therapeutics | 8-K: Current report

Oct 31, 2023 15:55

Plus Therapeutics | 8-K: Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 31, 2023 15:06

Plus Therapeutics | 8-K: Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 14, 2023 15:12

Plus Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Aug 9, 2023 06:55

Plus Therapeutics | 8-K: Current report

May 16, 2023 07:09

Plus Therapeutics | 8-K: Current report

Apr 28, 2023 15:34

Plus Therapeutics | 8-K: Current report

Apr 21, 2023 05:30

Plus Therapeutics | 8-K: Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 20, 2023 15:04

Plus Therapeutics | 8-K: Current report

Mar 13, 2023 05:30

Plus Therapeutics | DEF 14A: Definitive proxy statements

Mar 7, 2023 15:42

Plus Therapeutics | 8-K: Current report

Mar 3, 2023 15:31

Plus Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition

Feb 24, 2023 16:03